Zobrazeno 1 - 10
of 24
pro vyhledávání: '"33"'
Autor:
David Miles, Matthew Kent, Kenneth Russell, Mary K Downer, Patricia Luhn, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P2-15
Background: Corticosteroids (CS) have immunosuppressive properties that may diminish the efficacy of cancer immunotherapy (CIT). In retrospective analyses of clinical trial data, the use of CS for immune-mediated adverse events after starting CIT doe
Autor:
Dongling Gao, Nan Dong, Yuchen Han, Ruiying Zhao, Xue Wu, Zhihua Zhao, Qiuxiang Ou, Wencai Li, Guozhong Jiang, Xiaoling Tong
Publikováno v:
Cancer Research. 80:741-741
Background ROS1 gene rearrangements are reported at a prevalence of 1-2% in unselected cancer populations including non-small cell lung cancer (NSCLC), and notably higher in lung adenocarcinoma. More than twenty ROS1 fusion partners have been identif
Autor:
Sulan Yao, Jian Zhang, Xuejun Liang, Leiping Wang, Yanping Ji, Feng Tian, Xichun Hu, Gang Xia, Gaozhun Xiong
Publikováno v:
Cancer Research. 81:PS10-57
Background: ARX788 is a novel antibody drug conjugate (ADC) that consists of a human epidermal growth factor receptor 2 (HER2) targeting monoclonal antibody (mAb) site-specifically conjugated with payload AS269, a highly potent tubulin inhibitor. Res
Autor:
Junji Tsurutani, Haeseong Park, S. Takahashi, Yoshiaki Sagara, H. Iwata, Kazuo Tamura, Charles H. Redfern, Masahiro Sugihara, Toshihiko Doi, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Shanu Modi, Ian E. Krop, Yoshihiko Fujisaki, Caleb Lee, Rebecca Redman
Publikováno v:
Cancer Research. 79:P6-17
Background: HER2-targeted therapies have improved survival for advanced HER2-positive breast cancers (BC), but none have been approved for tumors with low levels of HER2 expression (ie, HER2 IHC 1+ or 2+/ISH-negative). Trastuzumab deruxtecan (DS-8201
Abstract P1-03-08: New diagnostic tools for bone health assessment: Perspectives in medical oncology
Publikováno v:
Cancer Research. 79:P1-03
Background Pituitary down regulators, aromatase inhibitors tamoxifen and chemotherapeutic drugs, all have a negative impact on bone health in breast cancer patients. Although trabecular bone accounts for only 20% of skeleton mass, bone resistance dep
Autor:
Matthew J. Ellis, Jo Anne Zujewski, Monica M. Mita, J. M. Guenther, Wajeeha Razaq, Anna Weiss, Kelly K. Hunt, T Dockter, Cynthia X. Ma, Olwen Hahn, Lisa A. Carey, Mark A. Watson, S Sanati, Horacio Maluf, Vera J. Suman, Yang Wang, Jeremy Hoog, Kiran Vij, Clifford A. Hudis, Gary Unzeitig, Tina J. Hieken, Amy Tiersten, Eric P. Winer, Ann H. Partridge, Erika C. Crouch, A. Marilyn Leitch, Abigail S. Caudle
Publikováno v:
Cancer Research. 81:GS4-05
Background: Ki67 values >10% 2-4 weeks (wks) after starting neoadjuvant ET (NET) indicates persistent cell proliferation, resistance to ET, and is associated with increased risk of recurrence. The ACOSOG Z1031 trial suggested that these tumors are al
Publikováno v:
Cancer Research. 77:P2-08
BACKGROUND Fulvestrant is a selective estrogen receptor degrader (SERD) with no known agonist effects. In the open-label Phase 2 FIRST study, fulvestrant 500 mg suggested improved efficacy as first-line treatment vs anastrozole in patients with hormo
Autor:
NK Ibrahim, S-C Tang, AJ Brenner, S Kesari, DE Piccioni, CK Anders, JA Carillo, P Chalasani, P Kabos, S Puhalla, AA Garcia, KH Tkaczuk, MS Ahluwalia, NJ Lakhani, P Kumthekar
Publikováno v:
Cancer Research. 77:P1-12
Background: The incidence of CNS metastatic disease in breast cancer patients (pts) seems to have increased in recent years with the improvement of systemic therapy. However, treatment options for CNS metastases have remained limited due to the inabi
Autor:
Seock-Ah Im, Gursel Aktan, Norikazu Masuda, David W. Cescon, Oleg Lipatov, Hiroji Iwata, Zbigniew Nowecki, Peter Schmid, Zifang Guo, Hope S. Rugo, Jose Perez-Garcia, Vassiliki Karantza, Marco Torregroza Otero, Carlos Gallardo, Sherene Loi, Mastura Md Yusof, Carlos Barrios, Erhan Gokmen, Jing Zhao, Javier Cortes
Publikováno v:
Cancer Research. 81:GS3-01
Background: Pembrolizumab (pembro) monotherapy showed durable antitumor activity and manageable safety in patients (pts) with metastatic triple-negative breast cancer (TNBC) in the KEYNOTE-012, -086, and -119 studies. In a prespecified interim analys
Publikováno v:
Cancer Research. 76:P4-14
Introduction: In the CLEOPATRA study, pertuzumab (P) plus trastuzumab (T) and docetaxel (D) significantly improved median progression-free survival (PFS) and overall survival (OS) compared with placebo (Pla) plus T and D in pts with HER2-positive met